388 related articles for article (PubMed ID: 20887245)
1. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.
Campa C; Harding SP
Curr Drug Targets; 2011 Feb; 12(2):173-81. PubMed ID: 20887245
[TBL] [Abstract][Full Text] [Related]
2. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
Zampros I; Praidou A; Brazitikos P; Ekonomidis P; Androudi S
J Ophthalmol; 2012; 2012():319728. PubMed ID: 22174998
[TBL] [Abstract][Full Text] [Related]
3. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
4. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
5. Neovascular age-related macular degeneration: potential therapies.
Chappelow AV; Kaiser PK
Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
[TBL] [Abstract][Full Text] [Related]
6. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
7. Neovascular Age-Related Macular Degeneration.
Shao J; Choudhary MM; Schachat AP
Dev Ophthalmol; 2016; 55():125-36. PubMed ID: 26501146
[TBL] [Abstract][Full Text] [Related]
8. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
9. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
10. Advances in pharmacotherapy for wet age-related macular degeneration.
Santarelli M; Diplotti L; Samassa F; Veritti D; Kuppermann BD; Lanzetta P
Expert Opin Pharmacother; 2015; 16(12):1769-81. PubMed ID: 26165696
[TBL] [Abstract][Full Text] [Related]
11. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
Scott AW; Bressler SB
Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
[TBL] [Abstract][Full Text] [Related]
13. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
[TBL] [Abstract][Full Text] [Related]
14. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
16. Preferred therapies for neovascular age-related macular degeneration.
Lally DR; Gerstenblith AT; Regillo CD
Curr Opin Ophthalmol; 2012 May; 23(3):182-8. PubMed ID: 22450218
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
18. [Antivasoproliferative agents in ophthalmology].
Ambresin A; Zografos L; Mantel I
Rev Med Suisse; 2010 Jan; 6(231):51-4. PubMed ID: 20196434
[TBL] [Abstract][Full Text] [Related]
19. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
Budzinskaya MV; Plyukhova AA; Sorokin PA
Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
[TBL] [Abstract][Full Text] [Related]
20. Defining response to anti-VEGF therapies in neovascular AMD.
Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
